
Q32 Bio Inc. — Investor Relations & Filings
Q32 Bio Inc. is a clinical-stage biotechnology company developing therapies to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's therapeutic approach targets powerful regulators of both the innate and adaptive immune systems. Its most advanced product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling from both interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). The candidate is currently being evaluated in a Phase 2 program for the treatment of alopecia areata.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| 10-Q - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | |
| 8-K - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | |
| ARS - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | |
| DEF 14A - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | |
| 424B5 - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-24 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47843637 | 8-K | 2026-05-27 | English | ||
| 41350292 | 10-Q - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | ||
| 41346460 | 8-K - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | ||
| 39072013 | ARS - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | ||
| 39069697 | DEF 14A - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | ||
| 36267508 | 424B5 - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-24 | English | ||
| 33003133 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 33003135 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 33003131 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 32896138 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 32896139 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 32896140 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 31187430 | 8-K Filing | 2026-02-17 | English | ||
| 31187392 | 424B5 Filing | 2026-02-17 | English | ||
| 31187419 | 4 Filing | 2026-01-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Biovica International B
Develops blood-based biomarker assays for cancer therapy mo…
|
BIOVIC | SE | Professional, scientific and te… |
|
Boji Medical Technology Co., Ltd.
A CRO providing full-service pharmaceutical and medical dev…
|
300404 | CN | Professional, scientific and te… |
|
Bonus BioGroup Ltd.
A clinical-stage biotech firm developing cell therapy and t…
|
BONS | IL | Professional, scientific and te… |
|
BPH GLOBAL LTD
Biotech firm focused on plant-based health products and fun…
|
BP8 | AU | Professional, scientific and te… |
|
BRAIN Biotech AG
Develops enzymes and microorganisms for the food, chemical,…
|
BNN | DE | Professional, scientific and te… |
|
BriaCell Therapeutics Corp.
Clinical-stage immuno-oncology company developing cellular …
|
BCTX | CA | Professional, scientific and te… |
|
Bright Minds Biosciences Inc.
Developing innovative serotonin-based drugs for neurologica…
|
DRUG | CA | Professional, scientific and te… |
|
BRIM
Develops therapies for ophthalmology and degenerative disea…
|
6885 | TW | Professional, scientific and te… |
|
BSF ENTERPRISE PLC
Develops cell-based solutions for cultivated meat, leather,…
|
BSFA | GB | Professional, scientific and te… |
|
BullFrog AI Holdings, Inc.
A technology company applying AI and machine learning to dr…
|
BFRG | US | Professional, scientific and te… |
Q32 Bio Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34891/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34891 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34891 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34891 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34891}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Q32 Bio Inc. (id: 34891)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.